BioMarin Pharma (BMRN) Tops Q1 EPS by 20c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.49 +1.06%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 GAAP EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $304 million versus the consensus estimate of $288.98 million.
Non-GAAP income for the first quarter ended March 31, 2017 was $35 million, compared to non-GAAP loss of $29 million for the quarter ended March 31, 2016.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Nike names former Pfizer CFO David Denton as new finance chief
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
